BHLHE22

Across TCGA pan-cancer cohorts, BHLHE22 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated BHLHE22 data layer compared with 20 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher BHLHE22 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated BHLHE22 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LUAD, LGG, and LUSC are the cancer types where BHLHE22 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	IV	0.342	0.893	<.001	12	view →
LGG	OS	Median	All	0.270	0.810	.002	9	view →
LUSC	DFS	Median	II,III,IV	0.135	0.663	.015	6	view →
UCEC	DFS	Median	All	0.963	0.627	.026	4	view →
COAD	OS	Median	III,IV	0.208	0.791	.008	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

BHLHE22–LUAD (DFS)

Open the LUAD breakdown →